Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M252Revenue (TTM) $M162Net Margin (%)-126.5Altman Z-Score-45.6
Enterprise Value $M435EPS (TTM) $-0.6Operating Margin %-119.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score4,128Pre-tax Margin (%)-126.5Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %-20.0Quick Ratio0.4Cash flow > EarningsY
Price/Sales1.65-y EBITDA Growth Rate %-14.6Current Ratio0.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-140.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M479ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with MNKD

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

MNKD is held by these investors:

MNKD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PFEFFER MATTHEW JCEO, CFO, Director 2017-01-03Buy4,540$0.54-1.85view
Alinaya Rosabel RealicaSVP, Prin Acctg Officer 2017-01-03Buy9,043$0.54-1.85view
Castagna MichaelChief Commercial Officer 2016-08-26Buy17,500$0.78-32.05view
Castagna MichaelChief Commercial Officer 2016-08-24Buy15,000$0.87-39.08view
Castagna MichaelChief Commercial Officer 2016-08-23Buy25,000$0.94-43.62view
PFEFFER MATTHEW JCEO, CFO, Director 2016-08-15Buy25,000$0.99-46.46view
Castagna MichaelChief Commercial Officer 2016-08-12Buy25,000$1-47view
Alinaya Rosabel RealicaSVP, Prin Acctg Officer 2016-07-06Sell6,294$1.06-50view
Castagna MichaelChief Commercial Officer 2016-05-17Buy50,000$0.93-43.01view
Martens JuergenCorporate VP and COO 2015-05-21Buy20,000$4.57-88.4view

Press Releases about MNKD :

Quarterly/Annual Reports about MNKD:

News about MNKD:

Articles On GuruFocus.com
Why MannKind Could Be a Value Trap Jan 04 2016 
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 

More From Other Websites
The 6 Most Shorted Nasdaq Stocks Feb 10 2017
MannKind Looks to Boost Flagging Afrezza Sales Feb 02 2017
Mannkind in Free Fall After Changes to Insulin Product, Sales Force Feb 02 2017
Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on... Feb 01 2017
MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza®... Feb 01 2017
MannKind Corporation to Hold Investor Conference Call on February 1, 2017 Jan 27 2017
Short Sellers Back Off Major Biotechs Jan 26 2017
The 6 Most Shorted Nasdaq Stocks Jan 26 2017
Insulin Drug Offers Hope for MannKind Jan 12 2017
Biotech Short Sellers Run for Cover Jan 12 2017
MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jan 12 2017
The 6 Most Shorted Nasdaq Stocks Jan 12 2017
MANNKIND CORP Files SEC form 8-K, Other Events Jan 10 2017
MannKind Receives $30.6 Million From Sanofi Jan 09 2017
CORRECTING AND REPLACING -- MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare... Jan 05 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)